Top

Published in:

01-09-2017 | Original Article

Clinical study of blood purification therapy in critical care in Japan: results from the survey research of the Japan Society for Blood Purification in Critical Care in 2013

Authors: Toshiaki Arimura, Masanori Abe, Hidetoshi Shiga, Hiroshi Katayama, Kazo Kaizu, Shigeto Oda

Published in: Journal of Artificial Organs | Issue 3/2017

Abstract

To clarify the clinical status of blood purification therapy (BPT) in critical care in Japan, we conducted a cohort study using data from a nationwide registry of the Japan Society for Blood Purification in Critical Care in 2013. We enrolled 2227 patients treated with BPT (female, 39.1%; mean age, 65.5 ± 12.1 years) in the intensive care units of 43 facilities. Patient characteristics, modes of BPT, and survival rate for each disease were investigated. In total, BPT was performed 3053 times. Continuous renal replacement therapy (CRRT) (57.9%) was the most common mode of BPT, followed by intermittent renal replacement therapy (20.2%) and direct hemoperfusion with the polymyxin B-immobilized fiber column (PMX-DHP) (11.5%). Nafamostat mesilate (84.9%) was most frequently used as the anticoagulant. The 28-day survival rate was 56.8% in all patients. The most common mode for acute kidney injury (AKI) and multiple organ failure was CRRT, while PMX-DHP and CRRT were most common for sepsis. There was no significant difference in survival rates among AKI stages 1–3. Survival rate (38.3%) was significantly lower in patients with acute lung injury (ALI) than in those with multiple organ failure (41.8%) and those with sepsis (46.6%). Multivariate regression analysis revealed that the APACHE II score and the presence of acute ALI and acute hepatic failure were significantly associated with death. This large-scale cohort study showed the clinical status of BPT in Japan. Further investigations are required to clarify the efficacy of BPT for critically ill patients.

Available only for authorised users

Ricci Z, Ronco C, D’Amico G, De Felice R, Rossi S, Bolgan I, Bonello M, Zamperetti N, Petras D, Salvatori G, Dan M, Piccinni P. Practice patterns in the management of acute renal failure in the critically ill patient: an international survey. Nephrol Dial Transplant. 2006;21:690–6.CrossRefPubMed

Uchino S, Kellum JA, Bellomo R, Doig GS, Morimatsu H, Morgera S, Schetz M, Tan I, Bouman C, Macedo E, Gibney N, Tolwani A, Ronco C, Beginning and Ending Supportive Therapy for the Kidney (BEST Kidney) Investigators. Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA. 2005;294:813–8.CrossRefPubMed

Hirasawa H. Indications for blood purification in critical care. Contrib Nephrol. 2010;166:21–30.CrossRefPubMed

Kobayashi H, Abe M, Murata Y, Maruyama T, Furukawa T, Oikawa O, Okada K. Low-density lipoprotein apheresis for corticosteroid-resistant skin lesions caused by cholesterol crystal embolism: a case report and review of the literature. J Artif Organs. 2015;18:285–9.CrossRefPubMed

Abe M, Okada K, Suzuki M, Nagura C, Ishihara Y, Fujii Y, Ikeda K, Kaizu K, Matsumoto K. Comparison of sustained hemodiafiltration with continuous venovenous hemodiafiltration for the treatment of critically ill patients with acute kidney injury. Artif Organs. 2010;34:331–8.CrossRefPubMed

Oda S, Sadahiro T, Hirayama Y, Nakamura M, Watanabe E, Tateishi Y, Hirasawa H. Non-renal indications for continuous renal replacement therapy: current status in Japan. Contrib Nephrol. 2010;166:47–53.CrossRefPubMed

Bagshaw SM, Uchino S, Bellomo R, Morimatsu H, Morgera S, Schetz M, Tan I, Bouman C, Macedo E, Gibney N, Tolwani A, Oudemans-van Straaten HM, Ronco C. Kellum JA; Beginning and Ending Supportive Therapy for the Kidney (BEST Kidney) Investigators. Septic acute kidney injury in critically ill patients: clinical characteristics and outcomes. Clin J Am Soc Nephrol. 2007;2:431–9.CrossRefPubMed

Oppert M, Engel C, Brunkhorst FM, Bogatsch H, Reinhart K, Frei U, Eckardt KU, Loeffler M, John S, German Competence Network Sepsis (Sepnet). Acute renal failure in patients with severe sepsis and septic shock—a significant independent risk factor for mortality: results from the German prevalence study. Nephrol Dial Transpl. 2008;23:904–9.CrossRef

Andres-Hernando A, Dursun B, Altmann C, Ahuja N, He Z, Bhargava R, Edelstein CE, Jani A, Hoke TS, Klein C, Faubel S. Cytokine production increases and cytokine clearance decreases in mice with bilateral nephrectomy. Nephrol Dial Transpl. 2012;27:4339–47.CrossRef

10.

Doi K, Leelahavanichkul A, Hu X, Sidransky KL, Zhou H, Qin Y, Eisner C, Schnermann J, Yuen PS, Star RA. Pre-existing renal disease promotes sepsis-induced acute kidney injury and worsens outcome. Kidney Int. 2008;74:1017–25.CrossRefPubMedPubMedCentral

11.

Leelahavanichkul A, Huang Y, Hu X, Zhou H, Tsuji T, Chen R, Kopp JB, Schnermann J, Yuen PS, Star RA. Chronic kidney disease worsens sepsis and sepsis-induced acute kidney injury by releasing high mobility group box protein-1. Kidney Int. 2011;80:1198–211.CrossRefPubMedPubMedCentral

12.

Shoji H. Extracorporeal endotoxin removal for the treatment of sepsis: endotoxin adsorption cartridge (Toraymyxin). Ther Apher Dial. 2014;7:108–14.CrossRef

13.

Kaizu K, Inada Y, Kawamura A, Oda S, Hirasawa H. Current status of blood purification in critical care in Japan. Contrib Nephrol. 2010;166:4–10.CrossRefPubMed

14.

Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med. 1985;13:818–29.CrossRefPubMed

15.

Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl. 2012;2:1–138.

16.

Vincent JL, Moreno R, Takala J, Willatts S, De Mendonça A, Bruining H, Reinhart CK, Suter PM, Thijs LG. The SOFA (Sepsisrelated Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med. 1996;22:707–10.CrossRefPubMed

17.

Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G; SCCM/ESICM/ACCP/ATS/SIS. 2001 SCCM/ESICM/ACCP/ATS/SIS international sepsis definitions conference. Crit Care Med. 2003;31:1250–6.

18.

Schrier RW, Wang W. Acute renal failure and sepsis. N Engl J Med. 2004;351:159–69.CrossRefPubMed

19.

Honore OM, Joannes-Boyau O, Boer W, Colln V. High-volume hemofiltration in sepsis and SIRS: current concept and future prospects. Blood Purif. 2009;28:1–11.CrossRefPubMed

20.

Nakada T, Hirasawa H, Oda S, Shiga H, Matsuda K. Blood purification for hypercytokinemia. Transfus Apher Sci. 2006;35:253–64.CrossRefPubMed

21.

Ronco C, Bellomo R, Homel P, Brendolan A, Dan M, Piccinni P, La Greca G. Effects of different doses in continuous venovenous haemofiltration on outcomes of acute renal failure: a prospective randomised trial. Lancet. 2000;356:26–30.CrossRefPubMed

22.

Garzotto F, Ostermann M, Martín-Langerwerf D, Sánchez-Sánchez M, Teng J, Robert R, Marinho A, Herrera-Gutierrez ME, Mao HJ, Benavente D, Kipnis E, Lorenzin A, Marcelli D, Tetta C, Ronco C, DoReMIFA study group. The dose response multicentre investigation on fluid assessment (DoReMIFA) in critically ill patients. Crit Care. 2016;20:196.CrossRefPubMedPubMedCentral

23.

Lorenzin A, Garzotto F, Alghisi A, Neri M, Galeano D, Aresu S, Pani A, Vidal E, Ricci Z, Murer L, Goldstein SL, Ronco C. CVVHD treatment with CARPEDIEM: small solute clearance at different blood and dialysate flows with three different surface area filter configurations. Pediatr Nephrol. 2016;31:1659–65.CrossRefPubMed

24.

Villa G, Ricci Z, Romagnoli S, Ronco C. Multidimensional approach to adequacy of renal replacement therapy in acute kidney injury. Contrib Nephrol. 2016;187:94–105.PubMed

25.

Ricci Z, Ronco C. Renal replacement therapy in the critically ill: getting it right. Curr Opin Crit Care. 2012;18:607–12.CrossRefPubMed

26.

Sakai Y. Polymethylmethacrylate membrane with a series of serendipity. Contrib Nephrol. 2010;173:137–47.CrossRef

27.

Watanabe E, Hirasawa H, Oda S, Matsuda K, Hatano M, Tokuhisa T. Extremely high-interleukin-6 blood levels and outcome in the critically ill are associated with tumor necrosis factor- and interleukin-1 related gene polymorphism. Crit Care Med. 2005;33:89–97.CrossRefPubMed

28.

Nakamura M, Oda S, Sadahiro T, Hirayama Y, Watanabe E, Tateishi Y, Nakada T, Hirasawa H. Treatment of severe sepsis and septic shock by CHDF using a PMMA membrane hemofilter as a cytokine modulator. Contrib Nephrol. 2010;166:73–82.CrossRefPubMed

29.

Nakada T, Oda S, Matsuda K, Sadahiro T, Nakamura M, Abe R. Continuous hemodiafiltration with PMMA hemofilter in the treatment of patients with septic shock. Mol Med. 2008;14:257–63.CrossRefPubMedPubMedCentral

30.

Matsuda K, Moriguchi T, Harii N, Goto J. Comparison of efficacy between continuous hemodiafiltration with a PMMA membrane hemofilter and a PAN membrane hemofilter in the treatment of a patient with septic acute renal failure. Transfus Apher Sci. 2009;40:49–53.CrossRefPubMed

31.

Iwagami M, Yasunaga H, Noiri E, Horiguchi H, Fushimi K, Matsubara T, Yahagi N, Nangaku M, Doi K. Potential survival benefit of polymyxin B hemoperfusion in septic shock patients on continuous renal replacement therapy: a propensity-matched analysis. Blood Purif. 2016;42:9–17.

32.

Wheeler AP, Bernard GR. Acute lung injury and the acute respiratory distress syndrome: a clinical review. Lancet. 2007;369:1553–65.CrossRefPubMed

33.

Abe S, Azuma A, Mukae H, Ogura T, Taniguchi H, Bando M, Sugiyama Y. Polymyxin B-immobilized fiber column (PMX) treatment for idiopathic pulmonary fibrosis with acute exacerbation: a multicenter retrospective analysis. Intern Med. 2012;51:1487–91.CrossRefPubMed

34.

Oishi K, Aoe K, Mimura Y, Murata Y, Sakamoto K, Koutoku W, Matsumoto T, Ueoka H, Yano M. Survival from an acute exacerbation of idiopathic pulmonary fibrosis with or without direct hemoperfusion with a Polymyxin B-immobilized fiber column: a retrospective analysis. Intern Med. 2016;55:3551–9.CrossRefPubMedPubMedCentral

35.

Matsuda K, Moriguchi T, Oda S, Hirasawa H. Efficacy of continuous hemodiafiltration with a cytokine-adsorbing hemofilter in the treatment of acute respiratory distress syndrome. Contrib Nephrol. 2010;166:83–92.CrossRefPubMed

36.

Shinozaki K, Oda S, Abe R, Tateishi Y, Yokoi T, Hirasawa H. Blood purification in fulminant hepatic failure. Contrib Nephrol. 2010;166:64–72.CrossRefPubMed

Title: Clinical study of blood purification therapy in critical care in Japan: results from the survey research of the Japan Society for Blood Purification in Critical Care in 2013
Authors: Toshiaki Arimura
Masanori Abe
Hidetoshi Shiga
Hiroshi Katayama
Kazo Kaizu
Shigeto Oda
Publication date: 01-09-2017
Publisher: Springer Japan
Published in: Journal of Artificial Organs / Issue 3/2017
Print ISSN: 1434-7229
Electronic ISSN: 1619-0904
DOI: https://doi.org/10.1007/s10047-017-0968-3

2024 ASCO Annual Meeting

Springer Medicine

Clinical study of blood purification therapy in critical care in Japan: results from the survey research of the Japan Society for Blood Purification in Critical Care in 2013

Abstract

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2017

Evaluation of endothelialization in the center part of graft using 3 cm vascular grafts implanted in the abdominal aortae of the rat

Total artificial heart implantation for biventricular failure due to eosinophilic myocarditis

Non-machinery dialysis that achieves blood purification therapy without using full-scale dialysis machines

Temporary biventricular support with extracorporeal membrane oxygenation: a feasible therapeutic approach for cardiogenic shock with multiple organ failure

Appropriate control time constant in relation to characteristics of the baroreflex vascular system in 1/R control of the total artificial heart

Anticoagulation therapy for a LVAD patient with acquired warfarin resistance